Update on nonpharmacologic treatment for heart failure_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

GUO Rui ,  LIU Hongyu

Department of Cardiac Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150010, P.R.China;

Corresponding author：

LIU Hongyu, Email: hyliu1963@163.com

Keywords：

Heart failure; nonpharmacologic treatment; mechanical circulatory support; cardiac resynchronization therapy; regenerative medicine

DOI：

10.7507/1007-4848.201605010

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Heart failure is a global problem that occurs in 38 million patients worldwide, and the number is dramatically increasing in elderly society. Meanwhile, heart dysfunction is also the most common disease among hospitalized patients more than 65 years, especially in high-income countries. Approximately, one million patients are hospitalized because of heart failure in the world every year. Drug therapy is currently the most popular treatment for heart failure in clinic, however, the effects are limited. Therefore, exploring novel treatment strategies gradually becomes a focus not only in basic but also in clinical research.

Citation： GUO Rui, LIU Hongyu. Update on nonpharmacologic treatment for heart failure. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2017, 24(5): 390-395. doi: 10.7507/1007-4848.201605010 Copy

1.	Braunwald E. The war against heart failure: the Lancet lecture. Lancet, 2015, 385(9970): 812-824.
2.	Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study. Circulation, 2014, 129(14): 1493-501.
3.	Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med, 1954, 37(3): 171-185.
4.	Bregman D, Cohen SR. Mechanical techniques of circulation support: a percutaneous intra-aortic balloon device. Artif Organs, 1983, 7(1): 38-48.
5.	Kretzschmar D, Schulze PC, Ferrari MW. Hemodynamic Performance of a novel Right Ventricular Assist Device(PERKAT®). ASAIO J, 2017, 63(2): 123-127.
6.	Ihdayhid AR, Chopra S, Rankin J, et al. Intra-aortic balloon pump: indications, efficacy, guidelines and future directions. Curr Opin Cardiol, 2014, 29(4): 285-292.
7.	Thiele H, Ohman EM, Desch S, et al. Steffen desch. management of cardiogenic shock. Eur Heart J, 2015, 36(20): 1223-1230.
8.	潘宏伟, 郭莹, 彭建强, 等. 主动脉内球囊反搏在急性心肌梗死并泵衰竭患者不同时机的应用. 中国动脉硬化杂志, 2014, 22(1): 65-68.
9.	Hill JD, O'Brien TG, Murray JJ, et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. N Engl J Med, 1972, 286(12): 629-634.
10.	Schmidt M, Tachon G, Devilliers C, et al. Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults. Intensive Care Med, 2013, 39(5): 838-846.
11.	Makdisi G, Wang IW. Extra corporeal membrane oxygenation(ECMO) review of a lifesaving technology. Thorac Dis, 2015, 7(7): E166-E176.
12.	Deakey ME. The odyssey of the artificial heart. Artificial Organs, 2000, 24(6): 405-411.
13.	Colombo D, Ammirati E. Cyclosporine in transplantation-a history of converging timelines. J Biol Regul Homeost Agents, 2011, 25(4): 493-504.
14.	Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol, 2008, 52(8): 587-598.
15.	Schumer EM, Black MC, Monreal G, et al. Left ventricular assist devices: current controversies and future directions. Eur Heart J, 2016, 37(46): 3434-3439.
16.	Portner PM, Oyer PE, Pennington DG, et al. Implantable electrical left ventricular assist system: bridge to transplantation and the future. Ann Thorac Surg, 1989, 47(1): 142-150.
17.	Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med, 2001, 345(20): 1435-1443.
18.	Prinzing A, Herold U, Berkefeld A, et al. Left ventricular assist devices-current state and perspectives. J Thorac Dis, 2016, 8(8): E660-E666.
19.	Cook JA, Shah KB, Tang DG, et al. The total artificial heart. J Thorac Dis, 2015, 7(12): 2172-2180.
20.	Silva G, Melica B, Pires de Morais G, et al. Percutaneous implantation of a ventricular partitioning device for treatment of ischemic heart failure: initial experience of a center. Rev Port Cardiol, 2012, 31(12): 795-801.
21.	Mazzaferri EL Jr, Gradinac S, Sagic D, et al. Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results of the PercutAneous Ventricular RestorAtion in Chronic Heart failure. Patients Trial. Am Heart J, 2012, 163: 812-820.
22.	马为, 洪涛, 李建平, 等. 经皮心室重建术—附两例病例报告. 中国介入心脏病学杂志, 2013, 21(5): 274-277.
23.	Hochleitner M, Hörtnagl H, Gschnitzer F, et al. Long-term efficacy of physiologic dual-chamber pacing in the treatment of end-stage idiopathic dilated cardiomyopathy. Am J Cardiol, 1992, 70(15): 1320-1325.
24.	Yu CM, Fung WH, Sanderson JE, et al. Understanding nonresponders of cardiac resynchronization therapy－current and future perspectives. J Cardiovasc Electrophysiol, 2005, 16(10): 1117-1124.
25.	Achilli A, Peraldo C, Puglisi A, et al. Prediction of response to cardiac resynchronization therapy: the selection of candidates for CRT(SCART) study. Pacing Clin Electrophysiol, 2006, 29(Suppl 2): S11-S19.
26.	Epstein AE, DiMarco JP, Yancy CW, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol, 2008, 51(21): e1-62.
27.	Menard C, Hagege AA, Agbulut O, et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet, 2005, 366(9490): 1005-1012.
28.	Xu C, Police S, Rao N, et al. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res, 2002, 91(6): 501-508.
29.	Brockbank KG, Piersma AH, Voerman JS, et al. Stromal cells (CFU-F) in normal and genetically anemic mouse strains. Acta Haematol, 1985, 74(2): 75-80.
30.	Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp, 1988, 136: 42-60.
31.	Chi C, Wang F, Tian G, et al. Adipose-derived stem cells from both visceral and subcutaneous fat deposits significantly improve contractile function of infarcted rat hearts. Cell Transplant, 2015, 24(11): 2337-2351.
32.	Mohsin S, Siddiqi S, Sussman MA, et al. Empowering adult stem cells for myocardial regeneration. Circ Res, 2011, 109(12): 1415-1428.
33.	Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol, 2003, 41(7): 1078-1083.
34.	Murry CE, Reinecke H, Pabon LM, et al. Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol, 2006, 47(9): 1777-1785.
35.	Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: paradoxes of passaging. Exp Hematol, 2004, 32(5): 414-425.
36.	Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factor. Cell, 2006, 126(4): 663-676.
37.	Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res, 2009, 104(4): e30-e41.
38.	Minami H, Tashiro K, Kawabata K, et al. Generation of brain microvascular endothelial-like cells from human induced pluripotent stem cells by co-culture with C6 glioma cells. PLoS One, 2015, 10(6): e0128890.
39.	Yoo CH, Na HJ, Lee DS, et al. Endothelial progenitor cells from human dental pulp-derived iPS cells as a therapeutic target for ischemic vascular diseases. Biomaterials, 2013, 34(33): 8149-8160.
40.	Matsuura K, Wada M, Okano T, et al. Creation of human cardiac cell sheets using pluripotent stem cells. Biochem Biophys Res Commun, 2012, 425(2): 321-327.
41.	Talkhabi M, Aghdami N, Baharvand H. Human cardiomyocyte generation from pluripotent stem cells: A state-of-art. Life Sci, 2016, 145: 98-113.
42.	Burridge PW, Elena Matsa E, Wu JC, et al. Chemically defined generation of human cardiomyocytes. Nat Methods, 2014, 11(8): 855-860.
43.	Tran TH, Wang X, Burcin M, et al. Wnt3a-induced mesoderm formation and cardiomyogenesis in human embryonic stem cells. Stem Cells, 2009, 27(8): 1869-1878.
44.	Kattman SJ, Witty AD, Keller G, et al. Stage-specific optimization of activin/nodal and bmp signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell, 2011, 8(2): 228-240.
45.	Zhang J, Klos M, Kamp TJ, et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res, 2012, 111(9): 1125-1136.
46.	Sirabella D, Cimetta E, Vunjak-Novakovic G. " The state of the heart”: Recent advances in engineering human cardiac tissue from pluripotent stem cells. Exp Biol Med (Maywood), 2015, 240(8): 1008-1018.
47.	Amano Y, Nishiguchi A, Sawa Y, et al. Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays. Acta Biomater, 2016, 33: 110-121.
48.	Yamanaka S. A fresh look at iPS cells. Cell, 2009, 137(1): 13-17.
49.	Beltrami AP, Barlucchi L, Anversa P, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114(6): 763-776.
50.	Bolli R, Chugh AR, Anversa P, et al. Effect of cardiac stem cells in patients with ischemic cardiomyopathy: initial results of the SCIPIO trial. Lancet, 2011, 378(9806): 1847-1857.
51.	Zaruba MM, Soonpaa M, Reuter S, et al. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation, 2010, 121(18): 1992-2000.
52.	Lalit PA, Salick MR, Nelson DO, et al. Lineage reprogramming of fibroblasts into proliferative induced cardiac progenitor cells by defined factors. Cell Stem Cell, 2016, 18(3): 354-367.
53.	Olivetti G, Capasso JM, Anversa P, et al. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res, 1990, 67(1): 23-34.
54.	Caulfield JB, Leinbach R, Gold H. The relationship of myocardial infarct size and prognosis. Circulation, 1976, 53(3 Suppl): I141-I144.

1. Braunwald E. The war against heart failure: the Lancet lecture. Lancet, 2015, 385(9970): 812-824.
2. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study. Circulation, 2014, 129(14): 1493-501.
3. Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med, 1954, 37(3): 171-185.
4. Bregman D, Cohen SR. Mechanical techniques of circulation support: a percutaneous intra-aortic balloon device. Artif Organs, 1983, 7(1): 38-48.
5. Kretzschmar D, Schulze PC, Ferrari MW. Hemodynamic Performance of a novel Right Ventricular Assist Device(PERKAT®). ASAIO J, 2017, 63(2): 123-127.
6. Ihdayhid AR, Chopra S, Rankin J, et al. Intra-aortic balloon pump: indications, efficacy, guidelines and future directions. Curr Opin Cardiol, 2014, 29(4): 285-292.
7. Thiele H, Ohman EM, Desch S, et al. Steffen desch. management of cardiogenic shock. Eur Heart J, 2015, 36(20): 1223-1230.
8. 潘宏伟, 郭莹, 彭建强, 等. 主动脉内球囊反搏在急性心肌梗死并泵衰竭患者不同时机的应用. 中国动脉硬化杂志, 2014, 22(1): 65-68.
9. Hill JD, O'Brien TG, Murray JJ, et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. N Engl J Med, 1972, 286(12): 629-634.
10. Schmidt M, Tachon G, Devilliers C, et al. Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults. Intensive Care Med, 2013, 39(5): 838-846.
11. Makdisi G, Wang IW. Extra corporeal membrane oxygenation(ECMO) review of a lifesaving technology. Thorac Dis, 2015, 7(7): E166-E176.
12. Deakey ME. The odyssey of the artificial heart. Artificial Organs, 2000, 24(6): 405-411.
13. Colombo D, Ammirati E. Cyclosporine in transplantation-a history of converging timelines. J Biol Regul Homeost Agents, 2011, 25(4): 493-504.
14. Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol, 2008, 52(8): 587-598.
15. Schumer EM, Black MC, Monreal G, et al. Left ventricular assist devices: current controversies and future directions. Eur Heart J, 2016, 37(46): 3434-3439.
16. Portner PM, Oyer PE, Pennington DG, et al. Implantable electrical left ventricular assist system: bridge to transplantation and the future. Ann Thorac Surg, 1989, 47(1): 142-150.
17. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med, 2001, 345(20): 1435-1443.
18. Prinzing A, Herold U, Berkefeld A, et al. Left ventricular assist devices-current state and perspectives. J Thorac Dis, 2016, 8(8): E660-E666.
19. Cook JA, Shah KB, Tang DG, et al. The total artificial heart. J Thorac Dis, 2015, 7(12): 2172-2180.
20. Silva G, Melica B, Pires de Morais G, et al. Percutaneous implantation of a ventricular partitioning device for treatment of ischemic heart failure: initial experience of a center. Rev Port Cardiol, 2012, 31(12): 795-801.
21. Mazzaferri EL Jr, Gradinac S, Sagic D, et al. Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results of the PercutAneous Ventricular RestorAtion in Chronic Heart failure. Patients Trial. Am Heart J, 2012, 163: 812-820.
22. 马为, 洪涛, 李建平, 等. 经皮心室重建术—附两例病例报告. 中国介入心脏病学杂志, 2013, 21(5): 274-277.
23. Hochleitner M, Hörtnagl H, Gschnitzer F, et al. Long-term efficacy of physiologic dual-chamber pacing in the treatment of end-stage idiopathic dilated cardiomyopathy. Am J Cardiol, 1992, 70(15): 1320-1325.
24. Yu CM, Fung WH, Sanderson JE, et al. Understanding nonresponders of cardiac resynchronization therapy－current and future perspectives. J Cardiovasc Electrophysiol, 2005, 16(10): 1117-1124.
25. Achilli A, Peraldo C, Puglisi A, et al. Prediction of response to cardiac resynchronization therapy: the selection of candidates for CRT(SCART) study. Pacing Clin Electrophysiol, 2006, 29(Suppl 2): S11-S19.
26. Epstein AE, DiMarco JP, Yancy CW, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol, 2008, 51(21): e1-62.
27. Menard C, Hagege AA, Agbulut O, et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet, 2005, 366(9490): 1005-1012.
28. Xu C, Police S, Rao N, et al. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res, 2002, 91(6): 501-508.
29. Brockbank KG, Piersma AH, Voerman JS, et al. Stromal cells (CFU-F) in normal and genetically anemic mouse strains. Acta Haematol, 1985, 74(2): 75-80.
30. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp, 1988, 136: 42-60.
31. Chi C, Wang F, Tian G, et al. Adipose-derived stem cells from both visceral and subcutaneous fat deposits significantly improve contractile function of infarcted rat hearts. Cell Transplant, 2015, 24(11): 2337-2351.
32. Mohsin S, Siddiqi S, Sussman MA, et al. Empowering adult stem cells for myocardial regeneration. Circ Res, 2011, 109(12): 1415-1428.
33. Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol, 2003, 41(7): 1078-1083.
34. Murry CE, Reinecke H, Pabon LM, et al. Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol, 2006, 47(9): 1777-1785.
35. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: paradoxes of passaging. Exp Hematol, 2004, 32(5): 414-425.
36. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factor. Cell, 2006, 126(4): 663-676.
37. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res, 2009, 104(4): e30-e41.
38. Minami H, Tashiro K, Kawabata K, et al. Generation of brain microvascular endothelial-like cells from human induced pluripotent stem cells by co-culture with C6 glioma cells. PLoS One, 2015, 10(6): e0128890.
39. Yoo CH, Na HJ, Lee DS, et al. Endothelial progenitor cells from human dental pulp-derived iPS cells as a therapeutic target for ischemic vascular diseases. Biomaterials, 2013, 34(33): 8149-8160.
40. Matsuura K, Wada M, Okano T, et al. Creation of human cardiac cell sheets using pluripotent stem cells. Biochem Biophys Res Commun, 2012, 425(2): 321-327.
41. Talkhabi M, Aghdami N, Baharvand H. Human cardiomyocyte generation from pluripotent stem cells: A state-of-art. Life Sci, 2016, 145: 98-113.
42. Burridge PW, Elena Matsa E, Wu JC, et al. Chemically defined generation of human cardiomyocytes. Nat Methods, 2014, 11(8): 855-860.
43. Tran TH, Wang X, Burcin M, et al. Wnt3a-induced mesoderm formation and cardiomyogenesis in human embryonic stem cells. Stem Cells, 2009, 27(8): 1869-1878.
44. Kattman SJ, Witty AD, Keller G, et al. Stage-specific optimization of activin/nodal and bmp signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell, 2011, 8(2): 228-240.
45. Zhang J, Klos M, Kamp TJ, et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res, 2012, 111(9): 1125-1136.
46. Sirabella D, Cimetta E, Vunjak-Novakovic G. " The state of the heart”: Recent advances in engineering human cardiac tissue from pluripotent stem cells. Exp Biol Med (Maywood), 2015, 240(8): 1008-1018.
47. Amano Y, Nishiguchi A, Sawa Y, et al. Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays. Acta Biomater, 2016, 33: 110-121.
48. Yamanaka S. A fresh look at iPS cells. Cell, 2009, 137(1): 13-17.
49. Beltrami AP, Barlucchi L, Anversa P, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114(6): 763-776.
50. Bolli R, Chugh AR, Anversa P, et al. Effect of cardiac stem cells in patients with ischemic cardiomyopathy: initial results of the SCIPIO trial. Lancet, 2011, 378(9806): 1847-1857.
51. Zaruba MM, Soonpaa M, Reuter S, et al. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation, 2010, 121(18): 1992-2000.
52. Lalit PA, Salick MR, Nelson DO, et al. Lineage reprogramming of fibroblasts into proliferative induced cardiac progenitor cells by defined factors. Cell Stem Cell, 2016, 18(3): 354-367.
53. Olivetti G, Capasso JM, Anversa P, et al. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res, 1990, 67(1): 23-34.
54. Caulfield JB, Leinbach R, Gold H. The relationship of myocardial infarct size and prognosis. Circulation, 1976, 53(3 Suppl): I141-I144.

Previous Article
Anti-apoptosis effect and mechanism of heme oxygenase-1 on lung injury after cardiopulmonary bypass
Next Article
Surgical effect of low birth weight children with congenital heart disease

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Update on nonpharmacologic treatment for heart failure

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content